Duyuru • May 14
Harvard Bioscience, Inc. Provides Earnings Guidance for the Second Quarter 2026 and Reaffirms Earnings Guidance for the Full Year 2026 Harvard Bioscience, Inc. provided earnings guidance for the second quarter 2026 and reaffirmed earnings guidance for the full year 2026. For the quarter, the company expects Revenue between $20.5 million and $22.5 million. The Company’s second quarter outlook reflects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance.
The Company is reaffirming its full-year guidance and anticipates a ramp in revenue in the second half of the year, driven by expected sales growth in higher margin NPI pipeline, which includes products for organoids and electroporation. The Company continues to expect Revenue growth between 2% and 4%. Duyuru • Apr 29
Harvard Bioscience, Inc. to Report Q1, 2026 Results on May 12, 2026 Harvard Bioscience, Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026 Duyuru • Apr 22
Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2026 Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2026. Duyuru • Mar 13
Harvard Bioscience, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026 Harvard Bioscience, Inc. provided earnings guidance for the First Quarter and Full Year 2026. For the quarter, the Company expects Revenue between $20.0 million and $22.0 million.
For the full year, the Company expects Revenue growth between 2% and 4%. Duyuru • Feb 26
Harvard Bioscience, Inc. to Report Q4, 2025 Results on Mar 12, 2026 Harvard Bioscience, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026 Duyuru • Jan 30
Harvard Bioscience, Inc. Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth Harvard Bioscience, Inc. announced a strategic consolidation of its manufacturing operations designed to enhance operational efficiency, strengthen execution, and accelerate cost-savings efforts. The Company will close its manufacturing facility in Holliston, MA and transition U.S. production to its manufacturing hub in Minneapolis, MN. Certain operations will also be relocated to facilities in Germany, Sweden, and the UK, aligning specific product lines with their designated center of excellence and most strategically advantageous logistical location. The Holliston facility will remain operational throughout 2026 to support continuity and customer service. The consolidation is expected to be completed by the first quarter of 2027. The Company has implemented a comprehensive, phased transition plan designed to prevent any disruption to order fulfillment, product quality, and technical support. Transition-related costs are expected to generate incremental operating expenses throughout 2026 and in the first half of 2027. This initiative is expected to result in approximately $3 million in cost savings in 2027, and once fully implemented, approximately $4 million in annual cost savings going forward. The savings include reduced overhead, SKU rationalization, improved asset utilization, and a targeted reconfiguration of the Company's workforce across impacted operations. The Company has also filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission containing additional details regarding the consolidation of operations. Duyuru • Nov 07
Harvard Bioscience, Inc. Provides Earnings Guidance for the Fourth Quarter of 2025 Harvard Bioscience, Inc. provided earnings guidance for the fourth quarter of 2025. For the quarter, the Company expects revenues of $22.5 million to $24.5 million and gross margin in the 58% to 60% range. Duyuru • Oct 30
Harvard Bioscience, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Harvard Bioscience, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 06, 2025 Duyuru • Oct 04
Harvard Bioscience Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market On October 2, 2025, Harvard Bioscience, Inc., received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until March 30, 2026, to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period. In order to be eligible to receive the Second Compliance Period, the Company applied to have its common stock transferred from the Nasdaq Global Market to the Nasdaq Capital Market. In connection with the grant of the Second Compliance Period, the application was approved and the Common Stock will move to the Nasdaq Capital Market effective at the opening of business on October 3, 2025. If at any time before March 30, 2026, the bid price of the Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance, subject to the Staff’s discretion to extend the minimum bid price compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Second Compliance Period, the Common Stock will become subject to delisting. In the event that the Company receives notice that the Common Stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and the Company’s Common Stock will continue to be listed and traded under the symbol “HBIO.” The Company intends to continue to monitor the closing bid price of the Common Stock between now and March 30, 2026, and will consider available options to regain compliance with the Minimum Bid Price Requirement, including effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules. Duyuru • Sep 09
Harvard Bioscience, Inc. Appoints Stephen Denelsky to Board of Directors and as Member of Nominating & Governance Committee, Effective September 5, 2025 On September 5, 2025, the Board of Directors of Harvard Bioscience, Inc. appointed Stephen DeNelsky to serve as a member of the Board, effective September 5, 2025. Mr. DeNelsky will serve as a Class I director with a term that will expire at the Company’s 2028 annual meeting of stockholders. Mr. DeNelsky was also appointed to serve as a member of the Nominating & Governance Committee of the Board. Mr. DeNelsky, age 57, is a Managing Director at Oaktree Capital Management, a position he has held since 2022. Mr. DeNelsky was previously a Managing Director at Marathon Asset Management from 2019 to 2022 and President at Life Sciences Alternative Funding from 2011 to 2019. Mr. DeNelsky also currently serves on the board of directors of Visioncare Inc. and previously served on the boards of Integrated Diagnostics and AMICAS, Inc. Mr. DeNelsky possesses thirty years of experience in the research, analysis, and valuation of public and private equities in the healthcare industry and has worked across several major sub-sectors of healthcare, including life sciences, pharmaceuticals, devices and services. Mr. DeNelsky earned his B.A. in Economics from the American University and his M.B.A. from the University of Maryland. Duyuru • Aug 12
Harvard Bioscience, Inc. Provides Earnings Guidance for the Third Quarter Ending September 30, 2025 Harvard Bioscience, Inc. provided earnings guidance for the third quarter ending September 30, 2025. For the quarter, the Company expects third quarter 2025 revenues of $19 million to $21 million. Duyuru • Jun 29
Harvard Bioscience, Inc. Provides Non-Compliance Update On June 18, 2025, Harvard Bioscience, Inc. (the Company") notified the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with the audit committee requirement set in Nasdaq Listing Rule 5605(c)(2)(A) (the Audit Committee Composition Requirement") due to the Company having only two members on the audit committee (the Audit Committee") of its Board of Directors (the Board"). The Company's current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick's resignation from the Board and the Audit Committee effective June 10, 2025. On June 26, 2025, the Company received a letter from the staff at the Listing Qualifications Department of Nasdaq (the "Staff") notifying the Company that the Staff had determined that the Company no longer complies with the Audit Committee Composition Requirement. The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable. Until such appointment, the Company plans to rely on the cure period set forth in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company's next annual meeting of stockholders or (ii) one year from Mr. Edrick's resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement. Duyuru • Jun 24
Harvard Bioscience Receives Nasdaq Non-Compliance Notice Regarding Audit Committee Requirement On June 18, 2025, Harvard Bioscience, Inc. (the Company") notified the Nasdaq Stock Market LLC (Nasdaq") that the Company is not in compliance with the audit committee requirement set in Nasdaq Listing Rule 5605(c)(2)(A) (the Audit Committee Composition Requirement") due to the Company having only two members on the audit committee (the Audit Committee") of its Board of Directors (the Board"). The Company's current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick's resignation from the Board and the Audit Committee effective June 10, 2025. The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable. Until such appointment, the Company plans to rely on the cure period set in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company's next annual meeting of stockholders or (ii) one year from Mr. Edrick's resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement. Duyuru • Jun 03
Harvard Bioscience, Inc. Announces Board and Committee Changes On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors of Harvard Bioscience, Inc., effective May 30, 2025. Mr. Loewald has been a director since October 2017. On June 2, 2025, the Board appointed John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors. Mr. Duke, age 54, currently serves as Chief Executive Officer of Plastic Molding Technology, a leading supplier of plastic components. Prior to joining PMT, Mr. Duke served as Executive Vice President and Chief Business Officer of Lyten, Inc., a manufacturer of advanced materials, and prior to that spent over twenty years in roles of increasing responsibility at Corning Incorporated, including eight years as a leader in Corning’s Life Sciences division. Mr. Duke earned a Bachelor of Science in Materials Science & Engineering from the University of Utah and a Master of Business Administration from Harvard University. Duyuru • May 06
Harvard Bioscience, Inc. to Report Q1, 2025 Results on May 12, 2025 Harvard Bioscience, Inc. announced that they will report Q1, 2025 results Pre-Market on May 12, 2025 Duyuru • Apr 23
Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2025 Harvard Bioscience, Inc., Annual General Meeting, Jun 02, 2025. Duyuru • Apr 17
Harvard Bioscience, Inc. Announces Bertrand Loy Not Standing for Re-Election as Lead Independent Director and as Member of the Audit Committee and the Nominating and Governance Committee Harvard Bioscience, Inc. announced that on April 10, 2025, Bertrand Loy informed the Company that he will not stand for re-election at the Company’s 2025 Annual Meeting. Mr. Loy’s decision was not a result of any disagreement or any matter relating to the Company’s operations, policies, or practices. Mr. Loy has served as a member of the Board since 2014 and currently serves as the Company’s Lead Independent Director and as a member of the Audit Committee and the Nominating and Governance Committee. Mr. Loy will continue to serve as a director and in such roles until the Company’s 2025 Annual Meeting. The Board expresses its appreciation to Mr. Loy for his service to the Company. Duyuru • Mar 12
Harvard Bioscience, Inc. Provides Earnings Guidance for the First Quarter of 2025 Harvard Bioscience, Inc. provided earnings guidance for the first quarter of 2025. For the quarter, the company expects revenues to be between $19 million to $21 million. New Risk • Nov 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €94.2m (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€94.2m market cap, or US$99.4m). Reported Earnings • Nov 09
Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.029 loss in 3Q 2023) Third quarter 2024 results: US$0.11 loss per share (further deteriorated from US$0.029 loss in 3Q 2023). Revenue: US$22.0m (down 13% from 3Q 2023). Net loss: US$4.80m (loss widened 288% from 3Q 2023). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings. Duyuru • Nov 08
Harvard Bioscience, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024 Harvard Bioscience, Inc. provided revenue guidance for the fourth quarter of 2024. For the quarter, the company expects revenue of $23 million to $26 million. Duyuru • Oct 03
Harvard Bioscience, Inc. to Showcase Innovative Technologies at Society for Neuroscience Annual Meeting 2024 Harvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 - 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ implantable telemetry platform, and the VivaMARS™ activity monitoring system. The Company will exhibit its organoid-centric mesh Microelectrode Array (MEA) platform, which continues to gain traction among the scientific and therapy development communities. Unlike traditional technologies, the new Mesh MEA organoid platform captures electrophysiology signals from inside the organoid in real time, providing researchers with exciting new insights into complex neural dynamics and brain disorders. The Mesh MEA platform is currently being evaluated at select test sites for neurological and cardiac research in addition to safety pharmacology and toxicology applications. The Company has also begun limited quantity shipments to early adopters, with full production expected in the first half of 2025. Duyuru • Sep 18
Harvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications At Safety Pharmacology Society Annual Meeting Harvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Safety Pharmacology Society (SPS) Annual Meeting being held from September 22-25, 2024, in San Diego. SDI™? Ponemah™? Data Management Platform Provides Integrated Preclinical Solution. The Company's Ponemah™? platform, known for its compliance with GLP standards, is a leading tool for managing and analyzing data from a wide range of preclinical studies. Ponemah also enables future use of machine learning algorithms to efficiently analyze large data pools. SoHo™? Implantable Real-Time Telemetry for Small Animal Models: Introduced earlier this year, the Company's SoHo telemetry system is now in use by leading preclinical researchers to support their testing needs. The small footprint of the SoHo telemetry solution allows researchers to carry out studies using a wide range of animal models in high density and more natural shared housing environments. The SoHo system's new power management features create opportunities for longer duration longitudinal studies, and the Ponemah platform integration provides a powerful tool for collecting, managing, analyzing and reporting study data. SoHo supports the customer's business needs by reducing space needs, operating costs and test cycle times, and enabling increased testing throughput. VivaMARS's high level of automation supports the customer's business needs By reducing operating expenses and test cycle time. At SPS, the Company will be presenting a poster authored in cooperation with a leading CRO customer providing initial results with the VivaMARS system. The VivaMARS system represents a fundamental advance in highly automated behavioral testing and is currently available for shipment. MCS™? Mesh MEA™? Organoid Platform: The Company will also be highlighting its considerable progress toward adoption of its organoid-centric mesh Microelectrode Array (MEA) platform. Designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology, the new Mesh MEA™? platform allows researchers to capture precise electrophysiology measurements from inside the living organoid in real time. In addition, the Mesh MEA platform is expected to provide an efficient in-vitro screening option designed to reduce large population small model testing. New Risk • Aug 12
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$11m Forecast net loss in 2 years: US$546k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$546k net loss in 2 years). Share price has been volatile over the past 3 months (8.2% average weekly change). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). New Risk • Aug 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 1.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Shareholders have been diluted in the past year (1.7% increase in shares outstanding). Reported Earnings • Aug 09
Second quarter 2024 earnings released: US$0.067 loss per share (vs US$0.023 loss in 2Q 2023) Second quarter 2024 results: US$0.067 loss per share (further deteriorated from US$0.023 loss in 2Q 2023). Revenue: US$23.1m (down 20% from 2Q 2023). Net loss: US$2.93m (loss widened 199% from 2Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 34% per year whereas the company’s share price has fallen by 30% per year. Duyuru • Aug 09
Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024 Harvard Bioscience, Inc. provided revenue guidance for the year 2024. For the year, the company expects revenue outlook to approximately $97 million to $102 million. Duyuru • Aug 02
Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Harvard Bioscience, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024 New Risk • Jul 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Board Change • Jul 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Alan Edrick was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • May 08
Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024 Harvard Bioscience, Inc. provided earnings guidance for the full year 2024. For the full year 2024, the company expects revenues to be approximately flat versus 2023. The company expects second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China. Duyuru • May 01
Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024 Harvard Bioscience, Inc. announced that they will report Q1, 2024 results Pre-Market on May 07, 2024 Duyuru • Apr 10
Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth Harvard Bioscience, Inc. announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million. Duyuru • Apr 04
Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024 Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024, at 11:00 Eastern Daylight. Agenda: To consider election of one Class III Director named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal; to ratify of the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; to consider approval, by a non-binding advisory vote, of the compensation of company named executive officers; and to consider Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof. New Risk • Mar 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Shareholders have been diluted in the past year (2.9% increase in shares outstanding). New Risk • Mar 08
New major risk - Revenue and earnings growth Earnings have declined by 6.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.5% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Reported Earnings • Mar 08
Full year 2023 earnings released: US$0.081 loss per share (vs US$0.23 loss in FY 2022) Full year 2023 results: US$0.081 loss per share (improved from US$0.23 loss in FY 2022). Revenue: US$112.3m (down 1.0% from FY 2022). Net loss: US$3.42m (loss narrowed 64% from FY 2022). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Duyuru • Mar 07
Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024 Harvard Bioscience, Inc. provided revenue guidance for the full year 2024. for the year, The company expects flat to modest revenue growth, also expect strong second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in Chinese market conditions. Duyuru • Mar 06
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting Harvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 11-13, 2024, in Salt Lake City. Complementing an already extensive product line, the new innovations provide new opportunities for advancing preclinical and organoid-focused therapy development. The Company’s GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system. By integrating these new applications in a single data management platform, the Ponemah system provides users with a powerful tool for managing and analyzing data across a range of studies. The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools. Together with the Ponemah platform, the SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens new opportunities for longitudinal studies. SoHo supports the customer’s business needs by reducing operating costs and test cycle times, enabling increased testing throughput. The VivaMARS system combines the Company’s infrared Panlab® activity monitoring technology with its Ponemah platform to create an integrated, GLP-compliant solution for real-time, high precision behavioral testing. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes. Duyuru • Feb 28
Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Harvard Bioscience, Inc. announced that they will report Q4, 2023 results After-Market on Mar 07, 2024 Reported Earnings • Nov 09
Third quarter 2023 earnings released: US$0.029 loss per share (vs US$0.082 loss in 3Q 2022) Third quarter 2023 results: US$0.029 loss per share (improved from US$0.082 loss in 3Q 2022). Revenue: US$25.4m (down 5.8% from 3Q 2022). Net loss: US$1.24m (loss narrowed 64% from 3Q 2022). Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year. Duyuru • Nov 08
Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023 Harvard Bioscience, Inc. provided revenue guidance for the year 2023. The company now expect fiscal 2023 revenue to be approximately flat as compared to 2022. Expected 2023 revenue includes an approximately 5% point headwind from discontinued products. Duyuru • Nov 07
Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference Harvard Bioscience, Inc. announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C. Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused research and therapy development by a broad range of customers. The latest advancements from the Company's Data Sciences International (DSI) preclinical business expand the reach of DSI's industry-leading, GLP-compliant Ponemah preclinical data management platform. These advancements include DSI's new SoHo implantable telemetry solution for small animal models and its VivaMARS™? high-capacity behavior monitoring system. Integrated with the Ponemah platform, the SoHo implantable real-time telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in a more natural shared housing environment. In addition, the SoHo solution allows data to be collected over longer time periods and opens exciting new opportunities for longitudinal studies. The SoHo solution is designed to support the customer's business needs by reducing operating costs and test cycle times, enabling increased testing throughput. The VivaMARS system combines the Company’s real-time high precision Panlab® activity monitoring technology with its Ponemah preclinical data management platform to create an integrated GLP-compliant solution. The system is ideally suited to meet the high throughput, automated neuropharmacology and neurotoxicology testing needs of CROs and pharma companies, in addition to longitudinal behavior studies carried out by leading research and academic institutes. From Multi Channel Systems team, the Company will exhibit its first organoid-centric mesh Microelectrode Array (MEA). Expanding its recognized leadership position in in-vitro MEA products, the new mesh MEA system allows researchers to capture precise electrophysiology measurements from inside the organoid in real time. This new mesh MEA technology is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology. The Company will present early research results using this novel technology in neuroscience studies. Duyuru • Oct 31
Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Harvard Bioscience, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 07, 2023 Recent Insider Transactions • Aug 23
President recently bought €101k worth of stock On the 17th of August, James Green bought around 25k shares on-market at roughly €4.03 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €272k worth in shares. New Risk • Aug 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Reported Earnings • Aug 09
Second quarter 2023 earnings released: US$0.023 loss per share (vs US$0.059 profit in 2Q 2022) Second quarter 2023 results: US$0.023 loss per share (down from US$0.059 profit in 2Q 2022). Revenue: US$28.8m (down 1.5% from 2Q 2022). Net loss: US$980.0k (down 140% from profit in 2Q 2022). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 8% per year. Duyuru • Aug 09
Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023 Harvard Bioscience, Inc. provided earnings guidance for full year 2023. For the year, the company expects revenues of approximately $116 million to $120 million. Buying Opportunity • Aug 08
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 23%. The fair value is estimated to be €5.23, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 17%. Duyuru • Jul 29
Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Harvard Bioscience, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 08, 2023 Buying Opportunity • Jun 29
Now 21% undervalued Over the last 90 days, the stock is up 47%. The fair value is estimated to be €6.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 17%. Duyuru • Jun 21
Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer Harvard Bioscience, Inc. announced the appointment of Jennifer Cote as the Company's Chief Financial Officer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Prior to joining Harvard Bioscience, Cote held various financial, strategy, and operating roles of increasing responsibility at Bose Corporation, a leading supplier of speakers, headphones, electronics and other related products for the consumer audio, automotive, health, and professional audio market. During her tenure at Bose, she led various teams as Head of Strategy Enablement and Finance Services for Boses Global Business Services organization, Head of Finance for Boses Headphones Business Unit, and Head of Global Business Operations and Head of Finance for Boses Professional Systems Division. Earlier in her career, Ms. Cote held various positions of increasing responsibility, including Audit Manager, at Arthur Andersen LLP. A Certified Public Accountant and Chartered Global Management Accountant, Cote holds a Bachelor of Science in Accountancy from Villanova University. Buying Opportunity • Jun 10
Now 22% undervalued Over the last 90 days, the stock is up 96%. The fair value is estimated to be €6.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 17%. Buying Opportunity • May 25
Now 20% undervalued Over the last 90 days, the stock is up 90%. The fair value is estimated to be €6.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 17%. Buying Opportunity • Apr 28
Now 21% undervalued Over the last 90 days, the stock is up 96%. The fair value is estimated to be €6.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 17%. Recent Insider Transactions • Mar 21
President recently bought €100k worth of stock On the 15th of March, James Green bought around 40k shares on-market at roughly €2.50 per share. This transaction amounted to 2.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €544k worth in shares. Breakeven Date Change • Mar 12
Forecast breakeven date moved forward to 2023 The 2 analysts covering Harvard Bioscience previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$500.0k in 2023. Earnings growth of 104% is required to achieve expected profit on schedule. Reported Earnings • Mar 10
Full year 2022 earnings released: US$0.23 loss per share (vs US$0.007 loss in FY 2021) Full year 2022 results: US$0.23 loss per share (further deteriorated from US$0.007 loss in FY 2021). Revenue: US$113.3m (down 4.7% from FY 2021). Net loss: US$9.52m (loss widened US$9.23m from FY 2021). Revenue is forecast to grow 8.5% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year and the company’s share price has also increased by 7% per year. Recent Insider Transactions • Dec 04
President recently bought €72k worth of stock On the 1st of December, James Green bought around 30k shares on-market at roughly €2.39 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €444k worth in shares. Breakeven Date Change • Nov 16
Forecast breakeven date pushed back to 2024 The 2 analysts covering Harvard Bioscience previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$6.30m in 2024. Average annual earnings growth of 123% is required to achieve expected profit on schedule. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Alan Edrick was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 10
Third quarter 2022 earnings released: US$0.082 loss per share (vs US$0.004 loss in 3Q 2021) Third quarter 2022 results: US$0.082 loss per share (further deteriorated from US$0.004 loss in 3Q 2021). Revenue: US$26.9m (down 9.2% from 3Q 2021). Net loss: US$3.41m (loss widened US$3.24m from 3Q 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 03
Harvard Bioscience, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Harvard Bioscience, Inc. announced that they will report Q3, 2022 results After-Market on Nov 08, 2022 Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Alan Edrick was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Alan Edrick was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Aug 20
President recently bought €125k worth of stock On the 17th of August, James Green bought around 40k shares on-market at roughly €3.14 per share. This was the largest purchase by an insider in the last 3 months. James has been a buyer over the last 12 months, purchasing a net total of €43k worth in shares. Breakeven Date Change • Aug 10
Forecast breakeven date pushed back to 2023 The 2 analysts covering Harvard Bioscience previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of US$3.20m in 2023. Average annual earnings growth of 115% is required to achieve expected profit on schedule. Reported Earnings • Aug 05
Second quarter 2022 earnings released: EPS: US$0.059 (vs US$0.01 loss in 2Q 2021) Second quarter 2022 results: EPS: US$0.059 (up from US$0.01 loss in 2Q 2021). Revenue: US$29.2m (flat on 2Q 2021). Net income: US$2.44m (up US$2.85m from 2Q 2021). Profit margin: 8.3% (up from net loss in 2Q 2021). Over the next year, revenue is forecast to grow 15%, compared to a 13% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jul 28
Harvard Bioscience, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Harvard Bioscience, Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 04, 2022 Recent Insider Transactions • Jun 19
President recently bought €107k worth of stock On the 15th of June, James Green bought around 30k shares on-market at roughly €3.57 per share. In the last 3 months, they made an even bigger purchase worth €140k. Despite this recent buy, James has been a net seller over the last 12 months, reducing personal holdings by €82k. Recent Insider Transactions • May 12
President recently bought €140k worth of stock On the 9th of May, James Green bought around 40k shares on-market at roughly €3.50 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, James has been a net seller over the last 12 months, reducing personal holdings by €189k. Breakeven Date Change • May 07
Forecast breakeven date pushed back to 2023 The 3 analysts covering Harvard Bioscience previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of US$7.40m in 2023. Average annual earnings growth of 73% is required to achieve expected profit on schedule. Reported Earnings • May 05
First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.017 loss in 1Q 2021) First quarter 2022 results: US$0.17 loss per share (down from US$0.017 loss in 1Q 2021). Revenue: US$28.8m (up 6.6% from 1Q 2021). Net loss: US$6.88m (loss widened US$6.21m from 1Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 33% per year, which means it is well ahead of earnings. Duyuru • Apr 27
Harvard Bioscience, Inc. Introduces Smartstudy™ First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth Harvard Bioscience, Inc. has introduced SmartStudy™, an innovative technology feature to its Buxco® Inhalation System aimed at supporting more precise results, cost savings, and improved productivity for preclinical researchers. Product demonstrations were conducted in-booth during the recent Society of Toxicology (SOT) annual meeting in San Diego and will be available again May 15-17 during the American Thoracic Society (ATS) conference in San Francisco. SmartStudy™ permits researchers running small animal aerosol inhalation and exposure studies to shut off delivery of the test article to individual subjects when they have received the desire dosage while other animals continue to receive dosing. This is an exclusive feature of the Buxco Inhalation System which reduces the margin of error by being able to stop the known delivery amount. Triggered based on targeted AIA, also known as delivered dose, the SmartStudy bypass ports automatically close off test article delivery for select subjects within a modular tower then provides them with fresh air. Driven through a combination of hardware – controllers and adaptor ports – and FinePointe software, SmartStudy™ provides researchers improved precision and cost savings through more accurate dose delivery and reduced diagnostics time. test material, and subject use. With AIA, researchers are presented with real-time aerosol amounts inhaled and deposited in subjects’ lungs, another exclusive of this system. By reporting these measures against real-time respiratory endpoints using FinePointe software, researchers can observe a direct correlation between dose and lung function over time. In addition, FinePointe software updates with this feature introduction add single click diagnostics, calibration and aerosol characterization for more time and money savings for researchers setting up their studies. The Buxco Inhalation System with SmartStudy™ is used in toxicology, bioaerosol, environmental, disease model and pharmaceutical applications for academic researchers, contract research organizations (CROs) and pharmaceutical companies. Duyuru • Apr 22
Harvard Bioscience, Inc. to Report Q1, 2022 Results on May 04, 2022 Harvard Bioscience, Inc. announced that they will report Q1, 2022 results Pre-Market on May 04, 2022 Duyuru • Apr 08
Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022 Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022, at 11:00 Eastern Daylight. Agenda: To consider the election of two Class I Directors named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2025 and until such Director's successor is duly elected and qualified or until his earlier resignation or removal; to consider the ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022; to consider the Adoption and approval of an amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance by 500,000 shares of common stock; to consider the Approval, by a non-binding advisory vote, of the compensation of our named executive officers; and to consider the Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof. Reported Earnings • Mar 09
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.007 loss per share (up from US$0.20 loss in FY 2020). Revenue: US$118.9m (up 17% from FY 2020). Net loss: US$288.0k (loss narrowed 96% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 9.3%, compared to a 25% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Duyuru • Feb 22
Harvard Bioscience, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Harvard Bioscience, Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 08, 2022 Duyuru • Jan 30
Harvard Bioscience, Inc. Announces Executive Changes On January 24, 2022, Harvard Bioscience, Inc. accepted the resignation of Ken Olson for personal reasons from his position as Chief Operating Officer of the Company effective January 31, 2022. Mr. Olson will assist on various projects and in the transition of the Chief Operating Officer role until his departure from the Company on December 31, 2022. Breakeven Date Change • Dec 31
Forecast breakeven date pushed back to 2022 The 3 analysts covering Harvard Bioscience previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of US$5.57m in 2022. Average annual earnings growth of 50% is required to achieve expected profit on schedule. Breakeven Date Change • Dec 31
Forecast breakeven date pushed back to 2022 The 3 analysts covering Harvard Bioscience previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of US$5.57m in 2022. Average annual earnings growth of 50% is required to achieve expected profit on schedule. Reported Earnings • Nov 05
Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.028 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$29.7m (up 23% from 3Q 2020). Net loss: US$170.0k (loss narrowed 85% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.